Article information
Resumen
Los agentes biológicos inhibidores del factor de necrosis tumoral alfa (anti-TNF) se constituyen en un avance muy significativo en el tratamiento de los pacientes con espondilitis anquilosante (EA), demostrando una notable mejoría de sus síntomas, de su función y de su calidad de vida. Sumado a esta excelente respuesta clínica, se ha demostrado igualmente mejoría de la inflamación, demostrada mediante pruebas de laboratorio y estudios de resonancia nuclear magnética. A pesar de esta clara evidencia, la conexión entre actividad inflamatoria y progresión estructural no está tan claramente establecida como en artritis reumatoide (AR), y la evidencia de la eficacia de los anti-TNF en la prevención de la progresión del daño radiológico crónico en EA es deficiente. Se revisan las evidencias y las teorías actuales respecto a este crucial tema y se hace mención del importante papel de la proteína DKK-1, inhibidora de la vía Wnt. Esta proteína ha emergido recientemente como un regulador fundamental en la biología ósea y se constituye en una conexión clave entre inflamación, osteoporosis y remodelación articular.
Palabras clave:
espondilitis anquilosante
anti-TNF
progresión radiográfica
proteína Dickkopf-1
Summary
The anti-TNF biological agents constitute a major advance in the treatment of patients with ankylosing spondylitis (AS) showing a remarkable improvement in symptoms of patients, their function and quality of life. In addition to this excellent clinical response, it has also been clearly demonstrated improvement of inflammation as evidenced by laboratory tests and MRI studies. Despite this clear evidence, the connection between inflammatory activity and structural progression is not as clearly established as in rheumatoid arthritis, and the evidence of anti-TNF therapy to prevent chronic EA radiological damage is poor. We review the evidence and current theories about this crucial issue and mention the important role of DKK-1 protein, an inhibitor of the Wnt pathway. This protein has recently emerged as a key regulator in bone biology and constitutes a key link between inflammation, osteoporosis and joint remodeling.
Key words:
spondylitis
ankylosing
tumor necrosis factor-alpha inhibitors
radiographic progression
Dickkopf-1 protein
Full text is only aviable in PDF
Referencias
[1.]
J. Zochling, J. Brandt, J. Braun.
The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis.
Rheumatology, 44 (2005), pp. 1483-1491
[2.]
N.J. Sheehan.
HLA-B27: what's new?.
Rheumatology, 49 (2010), pp. 621-631
[3.]
M. Breban.
Genetics of spondyloarthritis.
Best Pract Res Clin Rheumatol, 20 (2006), pp. 593-599
[4.]
W.A. Bautista-Molano, J.D. Londoño, C. Romero, M. Ávila, R.R. Valle.
Espondiloartritis y su asociación con el Complejo Mayor de Histocompatibilidad.
Rev Colomb Reumatol, 18 (2011), pp. 34-41
[5.]
N. Akkoc.
Are Spondyloarthropathies as Common as Rheumatoid Arthritis Worldwide? A Review.
Curr Rheum Rep, 10 (2008), pp. 371-378
[6.]
J. Braun, J. Sieper.
Ankylosing spondylitis.
Lancet, 369 (2007), pp. 1379-1390
[7.]
J. Márquez, L.F. Pinto, D.L. Candia, M. Restrepo, E. Uribe, O. Rincón, et al.
Espondiloartritis en el Hospital Pablo Tobón Uribe Descripción de una cohorte.
Rev Colomb Reumatol, 17 (2010), pp. 80-85
[8.]
J.D. Londoño, L.A. González, L.A. Ramírez, P. Santos, M. Ávila, A.M. Santos, et al.
Caracterización de las espondiloartropatías y determinación de factores de mal pronóstico en una población de pacientes colombianos.
Rev Colomb Reumatol, 12 (2005), pp. 195-207
[9.]
S. van der Linden, H.A. Valkenburg, A. Cats.
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.
Arthritis Rheum, 27 (1984), pp. 361-368
[10.]
S. Carette, D. Graham, H. Little, J. Rubenstein, P. Rosen.
The natural disease course of ankylosing spondylitis.
Arthritis Rheum, 26 (1983), pp. 186-190
[11.]
X. Baraliakos, J. Listing, A. von der Recke, J. Braun.
The Natural Course of Radiographic Progression in Ankylosing Spondylitis - Evidence for Major Individual Variations in a Large Proportion of Patients.
J Rheumatol, 36 (2009), pp. 997-1002
[12.]
R. Landewé, A.J. Wanders, H. Mielants, M. Dougados, D. van der Heijde.
Function in patients with ankylosing spondylitis is the resultant of patient reported disease activity and radiographic damage of the spine [abstract].
Ann Rheum Dis, 63 (2004), pp. 88-89
[13.]
P. Machado, R. Landewé, J. Braun, K.G. Hermann, D. Baker, D. van der Heijde.
Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis.
Ann Rheum Dis, 69 (2010), pp. 1465-1470
[14.]
D. van der Heijde, R. Landewé, S. van der Linden.
How Should Treatment Effect on Spinal Radiographic Progression in Patients With Ankylosing Spondylitis Be Measured?.
Arthritis Rheum, 52 (2005), pp. 1979-1985
[15.]
C. Escalas, S. Trijau, M. Dougados.
Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.
Rheumatology, 49 (2010), pp. 1317-1325
[16.]
H. Dagfinrud, T.K. Kvien, K.B. Hagen.
The Cochrane review of physiotherapy interventions for ankylosing spondylitis.
J Rheumatol, 32 (2005), pp. 1899-1906
[17.]
J. Chen, C. Liu.
Sulfasalazine for ankylosing spondylitis.
Cochrane Database Syst Rev, 18 (2005), pp. CD004800
[18.]
J. Chen, C. Liu, J. Lin.
Methotrexate for ankylosing spondylitis.
Cochrane Database Syst Rev, 18 (2006), pp. CD004524
[19.]
A. Calin, B.A.C. Dijkmans, P. Emery, M. Hakala, J. Kalden, M. Leirisalo-Repo, et al.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Ann Rheum Dis, 63 (2004), pp. 1594-1600
[20.]
D. van der Heijde, B. Dijkmans, P. Geusens, J. Sieper, K. DeWoody, P. Williamson, et al.
Efficacy and Safety of Infliximab in Patients With Ankylosing Spondylitis Results of a Randomized Placebo-Controlled Trial (ASSERT).
Arthritis Rheum, 52 (2005), pp. 582-591
[21.]
D. van der Heijde, M.H. Schiff, J. Sieper, A.J. Kivitz, R.L. Wong, H. Kupper, et al.
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
Ann Rheum Dis, 68 (2009), pp. 922-929
[22.]
R.D. Inman, J.C. Davis, D. van der Heijde, L. Diekman, J. Sieper, S.I. Kim, et al.
Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Arthritis Rheum, 58 (2008), pp. 3402-3412
[23.]
J. Braun, M. Bollow, L. Neure, et al.
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis.
Arthritis Rheum, 38 (1995), pp. 499-505
[24.]
J.C. Davis.
Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis.
Semin Arthritis Rheum, 34 (2004), pp. 668-677
[25.]
R. Landewé, D. van der Heijde.
A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: structural outcomes.
Clin Exp Rheumatol, 27 (2009), pp. S102-S107
[26.]
X. Baraliakos, J. Listing, M. Rudwaleit, H. Haibel, J. Brandt, J. Sieper, et al.
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.
Ann Rheum Dis, 66 (2007), pp. 910-915
[27.]
W. Huang, E.M. Schwarz.
Mechanisms of Bone Resorption and New Bone Formation in Spondyloarthropathies.
Curr Rheum Rep, 4 (2002), pp. 513-517
[28.]
D. van der Heijde, A.L. Pangan, M.H. Schiff, J. Braun, M. Borofsky, J. Torre, et al.
Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
Ann Rheum Dis, 67 (2008), pp. 1218-1221
[29.]
X. Baraliakos, J. Listing, C. Fritz, H. Haibel, R. Alten, G.R. Burmester, et al.
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years–early clinical response predicts long-term outcome.
Rheumatology, (2011),
[30.]
J. Zochling, X. Baraliakos, K.G. Hermann, J. Braun.
Magnetic resonance imaging in ankylosing spondylitis.
Curr Opin Rheumatol, 19 (2007), pp. 346-352
[31.]
M. Rudwaleit, X. Baraliakos, J. Listing, J. Brandt, J. Sieper, J. Braun.
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept.
Ann Rheum Dis, 64 (2005), pp. 1305-1310
[32.]
X. Baraliakos, J. Davis, W. Tsuji, J. Braun.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.
Arthritis Rheum, 52 (2005), pp. 1216-1223
[33.]
X. Baraliakos, J. Listing, M. Rudwaleit, H. Haibel, J. Brandt, J. Sieper, et al.
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.
Ann Rheum Dis, 66 (2007), pp. 910-915
[34.]
M.C.W. Creemers, M.J.A.M. Franssen, M.A. van ‘t Hof, F.W.J. Gribnau, L.B.A. van de Putte, P.L.C.M. van Riel.
Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system.
Ann Rheum Dis, 64 (2005), pp. 127-129
[35.]
K. Holliman.
No Clear Connection Between Inflammation & Disease Progression in AS TNF blockers decrease symptoms but seem to have little impact on structural damage.
The Rheumatologist, (octubre 2010),
[36.]
D. van der Heijde, R. Landewé, S. Einstein, P. Ory, D. Vosse, L. Ni, et al.
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.
Arthritis Rheum, 58 (2008), pp. 1324-1331
[37.]
D. van der Heijde, R. Landewé, X. Baraliakos, H. Houben, A. van Tubergen, P. Williamson, et al.
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
Arthritis Rheum, 58 (2008), pp. 3063-3070
[38.]
D. van der Heijde, D. Salonen, B.N. Weissman, R. Landewé, W.P. Maksymowych, H. Kupper, et al.
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.
Arthritis Res Ther, 11 (2009), pp. R127
[39.]
A. Spoorenberg, A. van Tubergen, R. Landewé, M. Dougados, S. van der Linden, H. Mielants, et al.
Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives.
Rheumatology, 44 (2005), pp. 789-795
[40.]
A. Wanders, D. Heijde, R. Landewé, J.M. Béhier, A. Calin, I. Olivieri, et al.
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
Arthritis Rheum, 52 (2005), pp. 1756-1765
[41.]
D. Poddubnyy, I.H. Song, J. Sieper.
A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs.
Clin Exp Rheumatol, 27 (2009), pp. S148-S151
[42.]
X. Baraliakos, J. Listing, J. Brandt, H. Haibel, M. Rudwaleit, J. Sieper, et al.
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.
Rheumatology, 46 (2007), pp. 1450-1453
[43.]
J.L. Andreu, T. Otón, J. Sanz.
Terapia anti-TNF en espondilitis anquilosante: control sintomático y modificación del daño estructural.
Reumatol Clin, 7 (2011), pp. 51-55
[44.]
J.C. Baker-LePain, M.C. Nakamura, N.E. Lane.
Effects of inflammation on bone: an update.
Curr Opin Rheumatol, 23 (2011), pp. 389-395
[45.]
D. Poddubnyy, H. Appel, J. Sieper.
Investigation of involved tissue in axial spondyloarthritis–what have we learnt from immunohistochemical studies?.
Best Pract Res Clin Rheumatol, 24 (2010), pp. 715-719
[46.]
D. Diarra, M. Stolina, K. Polzer, J. Zwerina, M.S. Ominsky, D. Dwyer, et al.
Dickkopf-1 is a master regulator of joint remodeling.
Nat Med, 13 (2007), pp. 156-163
[47.]
D. Daoussis, A.P. Andonopoulos.
The Emerging Role of Dickkopf-1 in Bone Biology: Is It the Main Switch Controlling Bone and Joint Remodeling?.
Semin Arthritis Rheum, (2011),
[48.]
S. Uderhardt, D. Diarra, J. Katzenbeisser, J.P. David, J. Zwerina, W. Richards, et al.
Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints.
Ann Rheum Dis, 69 (2010), pp. 592-597
[49.]
G. Schett, M. Rudwaleit.
Can we stop progression of ankylosing spondylitis?.
Best Pract Res Clin Rheumatol, 24 (2010), pp. 363-371
[50.]
R.J. Lories, F.P. Luyten, K. de Vlam.
Progress in spondylarthritis Mechanisms of new bone formation in spondyloarthritis.
Arthritis Res Ther, 11 (2009), pp. 221
[51.]
X. Zhang, J.E. Aubin, R.D. Inman.
Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitis.
Curr Opin Rheumatol, 15 (2003), pp. 387-393
Copyright © 2012. Asociación Colombiana de Reumatología
